Therapy Detail

Therapy Name Balsalazide + Parthenolide
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Balsalazide Carbadox Balsalazida [Spanish] Carbadox (balsalazide) is a 5-aminosalicylate (5-ASA) type drug that is FDA approved for the treatment of inflammation resulting from ulcerative colitis (, however, has also been demonstrated to induce apoptosis and decrease cell proliferation in cancer cells (PMID: 28108625).
Parthenolide Parthenolide is derived from Tanacetum parthenium and is an inhibitor of NF-kB and IL-1, which potentially results in apoptosis by blocking the activation of NF-kB in cancer cells (PMID: 21603970, PMID: 28108625).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown colorectal cancer not applicable Balsalazide + Parthenolide Preclinical - Cell culture Actionable In a preclinical study, the combination of Balsalazide and Parthenolide resulted in a synergistic effect, resulting in reduced cell viability and increased apoptotic activity in colorectal cancer cells in culture (PMID: 28108625). 28108625
Clinical Trial Phase Therapies Title Recruitment Status